Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Evelyn L. Rustia"'
Autor:
Ariel R, Topletz-Erickson, Anthony J, Lee, JoAl G, Mayor, Hao, Sun, Layth I, Abdulrasool, Evelyn L, Rustia, Luke N, Walker, Christopher J, Endres
Publikováno v:
Clinical Pharmacokinetics. 61:1761-1770
Tucatinib, a highly selective tyrosine kinase inhibitor of the human epidermal growth factor receptor 2 (HER2) approved for HER2-positive metastatic breast cancer, is cleared by hepatic metabolism and subsequent biliary excretion. Liver disease can a
Autor:
Ariel Topletz-Erickson, Anthony Lee, Evelyn L. Rustia, Hao Sun, JoAl G. Mayor, Layth I. Abdulrasool, Luke Walker, Christopher J. Endres
Publikováno v:
Clinical pharmacokinetics. 61(10)
Tucatinib is approved for treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. Understanding potential drug-drug interactions (DDIs) informs proper dosing when co-administering tucatinib with other therapies. The a